{"entity":{"id":"lymphoma-tx-uk-access","kind":"term","name":"What the NHS in England funds for lymphoma, appraisal by appraisal","aka":["NICE lymphoma appraisals","Lymphoma drug funding England","Cancer Drugs Fund lymphoma"],"tldr":"A drug licensed for lymphoma is not automatically available on the NHS: NICE appraises each use separately and can recommend it, fund it for a while through the Cancer Drugs Fund, or refuse it. This entry lists what NICE decided for each lymphoma treatment, with the reference number to check.","summary":"Every number below was opened on nice.org.uk on 29 September 2026 and the recommendation read; none is quoted from memory. The list covers England and Wales. Scotland decides separately through the Scottish Medicines Consortium.\n\nLarge B-cell lymphoma. TA874 recommends polatuzumab vedotin with R-CHP for untreated diffuse large B-cell lymphoma, but only where the International Prognostic Index score is 2 to 5. TA649 covers polatuzumab vedotin with bendamustine and rituximab in relapsed or refractory disease. TA872 recommends axicabtagene ciloleucel after two or more systemic therapies, and TA895 recommends it through the Cancer Drugs Fund for disease refractory to, or relapsing within twelve months of, first-line chemoimmunotherapy when an autologous transplant would be suitable. TA1048 recommends lisocabtagene maraleucel in the same second-line setting for diffuse large B-cell lymphoma, high-grade B-cell lymphoma, primary mediastinal large B-cell lymphoma and grade 3B follicular lymphoma, and TA1159 allows it after two or more lines with an instruction to use the least expensive suitable option. Tisagenlecleucel's diffuse large B-cell lymphoma appraisal, TA933, was terminated, so it is not routinely commissioned for this disease. TA927 recommends glofitamab after two or more systemic treatments, and TA1113 allows glofitamab with gemcitabine and oxaliplatin after one line of treatment in adults not eligible for an autologous transplant. TA954 recommends epcoritamab after two or more treatments, but only in people who have already had polatuzumab vedotin or cannot have it, and TA947 places loncastuximab tesirine behind the same condition. TA883 does not recommend tafasitamab with lenalidomide.\n\nFollicular lymphoma. TA243 recommends rituximab with one of several chemotherapy backbones for untreated symptomatic stage III and IV disease, and TA226 recommends rituximab maintenance after a response to first-line rituximab-chemotherapy; TA110 and TA137 are the earlier rituximab appraisals. TA513 covers obinutuzumab for untreated advanced disease and TA472 and TA629 cover it with bendamustine after rituximab. TA627 covers lenalidomide with rituximab in previously treated disease. Two refusals matter: TA892 does not recommend mosunetuzumab after two or more systemic therapies, and TA894 does not recommend axicabtagene ciloleucel after three or more. TA1139 allows epcoritamab after two or more lines with a stopping rule at three years. The tisagenlecleucel follicular appraisal, TA842, was terminated.\n\nMarginal zone lymphoma. TA1001 recommends zanubrutinib after at least one anti-CD20-based treatment.\n\nMantle cell lymphoma. TA1193 allows the TRIANGLE regimen in England: ibrutinib with R-CHOP alternating with R-DHAP or R-DHAOx, followed by ibrutinib alone, for untreated disease in adults for whom an autologous transplant is suitable. TA1184 allows acalabrutinib with bendamustine and rituximab for untreated disease in people not eligible for an autologous transplant. TA502 covers ibrutinib in relapsed or refractory disease and TA1081 allows zanubrutinib after one line of treatment, with an instruction to use the least expensive of the suitable options. TA677 covers brexucabtagene autoleucel after a BTK inhibitor. TA370 covers bortezomib in untreated disease. The lenalidomide appraisal, TA774, was terminated.\n\nWaldenstrom macroglobulinaemia. TA491 and TA795 cover ibrutinib, and TA833 recommends zanubrutinib after at least one treatment but only where bendamustine with rituximab would also be suitable. The ibrutinib with rituximab appraisal, TA608, was terminated.\n\nHodgkin lymphoma. TA1059 recommends brentuximab vedotin with doxorubicin, dacarbazine and vinblastine for untreated stage 3 or 4 CD30-positive Hodgkin lymphoma in adults, so A-AVD is funded first line in England; an earlier appraisal of the same question, TA594, had been terminated. There is no NICE appraisal of nivolumab with AVD in untreated disease, which is the largest single difference between England and the United States in this cancer. TA524, the Cancer Drugs Fund review of TA446, carries the current recommendation for brentuximab vedotin in relapsed or refractory CD30-positive Hodgkin lymphoma, for people who have already had an autologous transplant or at least two previous therapies when transplant or multi-agent chemotherapy are unsuitable. TA462 covers nivolumab and TA540, TA772 and TA967 cover pembrolizumab in relapsed or refractory classical Hodgkin lymphoma, TA967 down to the age of 3.\n\nT-cell lymphomas. TA478 covers brentuximab vedotin in relapsed or refractory systemic anaplastic large cell lymphoma and TA641 covers it in combination for untreated disease. TA577 recommends it for CD30-positive cutaneous T-cell lymphoma after at least one systemic therapy, restricted to mycosis fungoides stage 2B or over, primary cutaneous anaplastic large cell lymphoma or Sezary syndrome. TA754 recommends mogamulizumab for Sezary syndrome after at least one systemic treatment and for mycosis fungoides only at stage 2B or above after at least two. TA720 recommends chlormethine gel for early-stage (1A, 1B and 2A) mycosis fungoides-type cutaneous T-cell lymphoma. Pralatrexate, belinostat and romidepsin have no United Kingdom licence for peripheral T-cell lymphoma, which is why the relapsed T-cell lymphoma row differs so much between England and the United States.\n\nThe clinical guideline behind all of this is NG52, non-Hodgkin lymphoma: diagnosis and management, with NG47, haematological cancers: improving outcomes, setting out how services should be organised.\n\nCAR-T is commissioned nationally and delivered only at NHS England-designated centres after review by the national CAR-T clinical panel, which is why the practical question is often not whether a treatment is funded but how quickly a person can be referred to a centre that gives it.","asOf":"2026-09-29","links":[{"label":"NICE TA874: polatuzumab vedotin in combination for untreated diffuse large B-cell lymphoma","url":"https://www.nice.org.uk/guidance/ta874"},{"label":"NICE TA872: axicabtagene ciloleucel after 2 or more systemic therapies","url":"https://www.nice.org.uk/guidance/ta872"},{"label":"NICE TA1048: lisocabtagene maraleucel after first-line chemoimmunotherapy when a stem cell transplant is suitable","url":"https://www.nice.org.uk/guidance/ta1048"},{"label":"NICE TA927: glofitamab after 2 or more systemic treatments","url":"https://www.nice.org.uk/guidance/ta927"},{"label":"NICE TA1113: glofitamab with gemcitabine and oxaliplatin for relapsed or refractory diffuse large B-cell lymphoma","url":"https://www.nice.org.uk/guidance/ta1113"},{"label":"NICE TA954: epcoritamab after 2 or more systemic treatments","url":"https://www.nice.org.uk/guidance/ta954"},{"label":"NICE TA892: mosunetuzumab for relapsed or refractory follicular lymphoma (not recommended)","url":"https://www.nice.org.uk/guidance/ta892"},{"label":"NICE TA894: axicabtagene ciloleucel for relapsed or refractory follicular lymphoma (not recommended)","url":"https://www.nice.org.uk/guidance/ta894"},{"label":"NICE TA883: tafasitamab with lenalidomide (not recommended)","url":"https://www.nice.org.uk/guidance/ta883"},{"label":"NICE TA1184: acalabrutinib with bendamustine and rituximab for untreated mantle cell lymphoma","url":"https://www.nice.org.uk/guidance/ta1184"},{"label":"NICE TA1001: zanubrutinib for marginal zone lymphoma after anti-CD20-based treatment","url":"https://www.nice.org.uk/guidance/ta1001"},{"label":"NICE TA524: brentuximab vedotin for CD30-positive Hodgkin lymphoma","url":"https://www.nice.org.uk/guidance/ta524"},{"label":"NICE TA577: brentuximab vedotin for CD30-positive cutaneous T-cell lymphoma","url":"https://www.nice.org.uk/guidance/ta577"},{"label":"NICE TA754: mogamulizumab for previously treated mycosis fungoides and Sezary syndrome","url":"https://www.nice.org.uk/guidance/ta754"},{"label":"NICE TA720: chlormethine gel for mycosis fungoides-type cutaneous T-cell lymphoma","url":"https://www.nice.org.uk/guidance/ta720"},{"label":"NICE TA1059: brentuximab vedotin in combination for untreated stage 3 or 4 CD30-positive Hodgkin lymphoma","url":"https://www.nice.org.uk/guidance/ta1059"},{"label":"NICE TA833: zanubrutinib for Waldenstrom macroglobulinaemia","url":"https://www.nice.org.uk/guidance/ta833"},{"label":"NICE TA1081: zanubrutinib for relapsed or refractory mantle cell lymphoma","url":"https://www.nice.org.uk/guidance/ta1081"},{"label":"NICE NG52: non-Hodgkin lymphoma, diagnosis and management","url":"https://www.nice.org.uk/guidance/ng52"},{"label":"NICE NG47: haematological cancers, improving outcomes","url":"https://www.nice.org.uk/guidance/ng47"},{"label":"NICE TA1193: ibrutinib with R-CHOP for untreated mantle cell lymphoma when a stem cell transplant is suitable","url":"https://www.nice.org.uk/guidance/ta1193"}],"tags":[],"related":[],"cancers":["dlbcl","follicular-lymphoma","mantle-cell-lymphoma","marginal-zone-lymphoma","waldenstrom","hodgkin-lymphoma","cutaneous-t-cell-lymphoma","peripheral-t-cell-lymphoma","non-hodgkin-lymphoma"],"sections":[],"technologies":[],"targets":[],"drugs":["polatuzumab-vedotin","axicabtagene-ciloleucel","lisocabtagene-maraleucel","tisagenlecleucel","brexucabtagene-autoleucel","glofitamab","epcoritamab","mosunetuzumab","zynlonta","tafasitamab","obinutuzumab","lenalidomide","rituximab","zanubrutinib","acalabrutinib","ibrutinib","bortezomib","brentuximab-vedotin","nivolumab","pembrolizumab","mogamulizumab","mechlorethamine","pralatrexate","belinostat","romidepsin"],"companies":[],"institutions":[],"pathways":[],"terms":["cancer-drugs-fund","lymphoma-tx-uk-versus-us"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"category":"Regulation & policy"},"route":"/terms/lymphoma-tx-uk-access/","neighbours":{"cancer":[{"id":"advanced-stage-classical-hodgkin-lymphoma","kind":"cancer","name":"Advanced-stage classical Hodgkin lymphoma (stage III to IV)","route":"/cancers/advanced-stage-classical-hodgkin-lymphoma/"},{"id":"cutaneous-t-cell-lymphoma","kind":"cancer","name":"Cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome)","route":"/cancers/cutaneous-t-cell-lymphoma/"},{"id":"dlbcl","kind":"cancer","name":"Diffuse large B-cell lymphoma","route":"/cancers/dlbcl/"},{"id":"early-stage-classical-hodgkin-lymphoma","kind":"cancer","name":"Early-stage classical Hodgkin lymphoma (stage I to II)","route":"/cancers/early-stage-classical-hodgkin-lymphoma/"},{"id":"follicular-lymphoma","kind":"cancer","name":"Follicular lymphoma","route":"/cancers/follicular-lymphoma/"},{"id":"hodgkin-lymphoma","kind":"cancer","name":"Hodgkin lymphoma","route":"/cancers/hodgkin-lymphoma/"},{"id":"mantle-cell-lymphoma","kind":"cancer","name":"Mantle cell lymphoma","route":"/cancers/mantle-cell-lymphoma/"},{"id":"marginal-zone-lymphoma","kind":"cancer","name":"Marginal zone lymphoma","route":"/cancers/marginal-zone-lymphoma/"},{"id":"non-hodgkin-lymphoma","kind":"cancer","name":"Non-Hodgkin lymphoma (all types)","route":"/cancers/non-hodgkin-lymphoma/"},{"id":"peripheral-t-cell-lymphoma","kind":"cancer","name":"Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma)","route":"/cancers/peripheral-t-cell-lymphoma/"},{"id":"relapsed-refractory-hodgkin-lymphoma","kind":"cancer","name":"Relapsed and refractory classical Hodgkin lymphoma","route":"/cancers/relapsed-refractory-hodgkin-lymphoma/"},{"id":"waldenstrom","kind":"cancer","name":"Waldenström macroglobulinaemia","route":"/cancers/waldenstrom/"}],"drug":[{"id":"acalabrutinib","kind":"drug","name":"Acalabrutinib","route":"/drugs/acalabrutinib/"},{"id":"axicabtagene-ciloleucel","kind":"drug","name":"Axicabtagene ciloleucel","route":"/drugs/axicabtagene-ciloleucel/"},{"id":"belinostat","kind":"drug","name":"Belinostat","route":"/drugs/belinostat/"},{"id":"bortezomib","kind":"drug","name":"Bortezomib","route":"/drugs/bortezomib/"},{"id":"brentuximab-vedotin","kind":"drug","name":"Brentuximab vedotin","route":"/drugs/brentuximab-vedotin/"},{"id":"brexucabtagene-autoleucel","kind":"drug","name":"Brexucabtagene autoleucel","route":"/drugs/brexucabtagene-autoleucel/"},{"id":"epcoritamab","kind":"drug","name":"Epcoritamab","route":"/drugs/epcoritamab/"},{"id":"glofitamab","kind":"drug","name":"Glofitamab","route":"/drugs/glofitamab/"},{"id":"ibrutinib","kind":"drug","name":"Ibrutinib","route":"/drugs/ibrutinib/"},{"id":"lenalidomide","kind":"drug","name":"Lenalidomide","route":"/drugs/lenalidomide/"},{"id":"lisocabtagene-maraleucel","kind":"drug","name":"Lisocabtagene maraleucel","route":"/drugs/lisocabtagene-maraleucel/"},{"id":"zynlonta","kind":"drug","name":"Loncastuximab tesirine","route":"/drugs/zynlonta/"},{"id":"mechlorethamine","kind":"drug","name":"Mechlorethamine (chlormethine)","route":"/drugs/mechlorethamine/"},{"id":"mogamulizumab","kind":"drug","name":"Mogamulizumab","route":"/drugs/mogamulizumab/"},{"id":"mosunetuzumab","kind":"drug","name":"Mosunetuzumab","route":"/drugs/mosunetuzumab/"},{"id":"nivolumab","kind":"drug","name":"Nivolumab","route":"/drugs/nivolumab/"},{"id":"obinutuzumab","kind":"drug","name":"Obinutuzumab","route":"/drugs/obinutuzumab/"},{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"},{"id":"polatuzumab-vedotin","kind":"drug","name":"Polatuzumab vedotin","route":"/drugs/polatuzumab-vedotin/"},{"id":"pralatrexate","kind":"drug","name":"Pralatrexate","route":"/drugs/pralatrexate/"},{"id":"rituximab","kind":"drug","name":"Rituximab","route":"/drugs/rituximab/"},{"id":"romidepsin","kind":"drug","name":"Romidepsin","route":"/drugs/romidepsin/"},{"id":"tafasitamab","kind":"drug","name":"Tafasitamab","route":"/drugs/tafasitamab/"},{"id":"tisagenlecleucel","kind":"drug","name":"Tisagenlecleucel","route":"/drugs/tisagenlecleucel/"},{"id":"zanubrutinib","kind":"drug","name":"Zanubrutinib","route":"/drugs/zanubrutinib/"}],"term":[{"id":"lymphoma-tx-uk-versus-us","kind":"term","name":"British and American lymphoma practice: where they differ, and why","route":"/terms/lymphoma-tx-uk-versus-us/"},{"id":"cancer-drugs-fund","kind":"term","name":"Cancer Drugs Fund (England)","route":"/terms/cancer-drugs-fund/"}]}}